SCHEMBL6947272

SCHEMBL6947272

Cc1c(Cl)nc(SCc2ccc3c(c2)OCO3)nc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HPGD P15428 4/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 2/20 0.51
PKM P14618 2/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.48
TP53 P04637 1/20 0.47
DAO P14920 1/20 0.46
NPC1 O15118 1/20 0.44
MAPT P10636 4/20 0.44
HTT P42858 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.42
ALOX12 P18054 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6939960 0.83 ALDH1A1 (0.54) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL6939968 0.82 ALDH1A1 (0.51) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL6946080 0.77 NOS2 (0.59)
SCHEMBL6942100 0.77 KCNH2 (0.57) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL6943927 0.76 NPC1 (0.50) ALDH1A1RAB9ASMN1; SMN2KMT2ATDP1
SCHEMBL6391680 0.74 CYP1A2 (0.43) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL1411847 0.74 ALDH1A1 (0.55) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL8794042 0.73 ALDH1A1 (0.57) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL22705531 0.71 TAAR1 (0.55) ALDH1A1HPGDRAB9AMAPTGAA
SCHEMBL17548459 0.70 HTT (0.41) ALDH1A1RAB9ASMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 ALDH1A1 573/4885HPGD 35/4885RAB9A 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.